37623878|t|Anti-Pyretic, Analgesic, and Anti-Inflammatory Activities of Meloxicam and Curcumin Co-Encapsulated PLGA Nanoparticles in Acute Experimental Models.
37623878|a|Herein, we evaluated the in vivo effects of meloxicam and curcumin co-encapsulated PLGA nanoparticles in experimental acute models of pyrexia, nociception, and inflammation. Seven groups (n = 6) were designed for each investigation and pretreated intraperitoneally (i.p.): the control group, meloxicam (4 mg/kg b.w.), curcumin (15 mg/kg b.w.), and equivalent content containing PLGA capped nanoparticles of meloxicam (Mlx-NP) and curcumin (Cur-NP) alone and in combination (Mlx-Cur-NP; at two doses). The results showed that PLGA encapsulation significantly (p <= 0.05) improved the in vivo activities of each compound. Furthermore, co-encapsulation of meloxicam and curcumin potentiated the anti-pyretic effect on yeast-induced pyretic rats, anti-nociceptive effect on nociception induced in rats by formalin and heat, and anti-edematogenic activity in xylene-induced ear edema in rats in a dose-dependent manner. In carrageenan-induced paw inflammation in rats, meloxicam and curcumin co-loading (Mlx-Cur-NP) resulted in significant (p <= 0.05) inhibition of paw inflammation, reduction in TNF-alpha and PGE2 levels, downregulation of expressions of pro-inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6), as well as a decrease in histopathological changes and TNF-alpha immunoexpression in paw tissues. Moreover, Mlx-Cur-NP demonstrated noteworthy potentiation in pharmacological effects compared to free compounds and mono-compound-loaded nanoparticles. Thus, the association of meloxicam with curcumin in a biodegradable nanocarrier system could provide a promising anti-pyretic, anti-nociceptive, and anti-inflammatory therapeutic approach for acute conditions.
37623878	34	46	Inflammatory	Disease	MESH:D007249
37623878	61	70	Meloxicam	Chemical	MESH:D000077239
37623878	75	83	Curcumin	Chemical	MESH:D003474
37623878	100	104	PLGA	Chemical	MESH:D000077182
37623878	193	202	meloxicam	Chemical	MESH:D000077239
37623878	207	215	curcumin	Chemical	MESH:D003474
37623878	232	236	PLGA	Chemical	MESH:D000077182
37623878	283	290	pyrexia	Disease	MESH:D005334
37623878	309	321	inflammation	Disease	MESH:D007249
37623878	441	450	meloxicam	Chemical	MESH:D000077239
37623878	467	475	curcumin	Chemical	MESH:D003474
37623878	527	531	PLGA	Chemical	MESH:D000077182
37623878	556	565	meloxicam	Chemical	MESH:D000077239
37623878	567	571	Mlx-	Chemical	-
37623878	579	587	curcumin	Chemical	MESH:D003474
37623878	589	593	Cur-	Chemical	-
37623878	623	633	Mlx-Cur-NP	Chemical	-
37623878	674	678	PLGA	Chemical	MESH:D000077182
37623878	802	811	meloxicam	Chemical	MESH:D000077239
37623878	816	824	curcumin	Chemical	MESH:D003474
37623878	950	958	formalin	Chemical	MESH:D005557
37623878	978	990	edematogenic	Disease	
37623878	1003	1009	xylene	Chemical	MESH:D014992
37623878	1018	1027	ear edema	Disease	MESH:D004427
37623878	1067	1078	carrageenan	Chemical	MESH:D002351
37623878	1091	1103	inflammation	Disease	MESH:D007249
37623878	1113	1122	meloxicam	Chemical	MESH:D000077239
37623878	1127	1135	curcumin	Chemical	MESH:D003474
37623878	1148	1158	Mlx-Cur-NP	Chemical	-
37623878	1214	1226	inflammation	Disease	MESH:D007249
37623878	1241	1250	TNF-alpha	Gene	24835
37623878	1305	1317	inflammatory	Disease	MESH:D007249
37623878	1329	1338	TNF-alpha	Gene	24835
37623878	1340	1348	IL-1beta	Gene	24494
37623878	1354	1358	IL-6	Gene	24498
37623878	1416	1425	TNF-alpha	Gene	24835
37623878	1469	1479	Mlx-Cur-NP	Chemical	-
37623878	1636	1645	meloxicam	Chemical	MESH:D000077239
37623878	1651	1659	curcumin	Chemical	MESH:D003474
37623878	1765	1777	inflammatory	Disease	MESH:D007249

